ReviewFrontiers in pharmacology2024
Enhancing health and therapeutic potential: innovations in the medicinal and pharmaceutical properties of soy bioactive compounds.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Finger millet and soybean as functional ingredients in next-generation fermented foods: a review of nutritional, technological, and health-promoting perspectives.Frontiers in nutrition · 2026Pooled it
- Biochar and ZnO-Se nanocomposites enhanced biochemical and antioxidant profiling of soybean: insight into GC-MS metabolomics, and KEGG pathway analysis.BMC plant biology · 2026Article
- Therapeutic Efficacy of Soy-Derived Bioactives: A Systematic Review of Nutritional Potency, Bioactive Therapeutics, and Clinical Biomarker Modulation.Foods (Basel, Switzerland) · 2025Review
- Perspective: Isoflavones-Intriguing Molecules but Much Remains to Be Learned about These Soybean Constituents.Advances in nutrition (Bethesda, Md.) · 2025Review
- The Role of Genistein in Type 2 Diabetes and Beyond: Mechanisms and Therapeutic Potential.Molecules (Basel, Switzerland) · 2025Review
- Chitosan-Based Nanoparticles Targeted Delivery System: In Treatment Approach for Dyslipidemia.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An extensive examination of the medical uses of soybean bioactive components is provided by this thorough review. It explores the possible health advantages of isoflavones with phytoestrogenic qualities, like genistein, which may lower the risk of cancer. The review highlights the different roles and possible anticancer activities of phenolic compounds, phytic acid, protease inhibitors, lignans, and saponins, among other bioactive components. It also addresses the benefits of dietary fiber and oligosaccharides derived from soybeans for intestinal health, as well as the impact of soy protein on diabetes, obesity, cancer, and cardiovascular health. Conjugated linoleic acid (CLA) has anticancer and cholesterol-lowering properties; its involvement in promoting metabolic processes is also examined. Pinitol is highlighted in the study as a blood sugar regulator with promise for controlling insulin signaling. In this review, we aim to affirm soybeans' potential as a high-functional, well-being food by examining their recently discovered therapeutic and pharmacological capabilities, rather than to improve upon the previous studies on the reported nutritional advantages of soybeans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.